Tiziana Life Sciences PLC (LON:TILS – Get Rating) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 58.50 ($0.69) and traded as low as GBX 45 ($0.53). Tiziana Life Sciences shares last traded at GBX 58.50 ($0.69), with a volume of 297,127 shares changing hands.
Tiziana Life Sciences Stock Up 8.3 %
The company has a quick ratio of 6.41, a current ratio of 6.54 and a debt-to-equity ratio of 2.36. The company has a market capitalization of £113.85 million and a price-to-earnings ratio of -3.59. The stock’s fifty day moving average price is GBX 58.50 and its 200-day moving average price is GBX 58.50.
Tiziana Life Sciences Company Profile
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. Its product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma.
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.